Abstract:Background Icotinib has provided survival benefits for patients with advanced, epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). We aimed to compare icotinib with chemotherapy in patients with EGFR-mutant stage II-IIIA NSCLC after complete tumour resection. Here, we report the results from the preplanned interim analysis of the study. Methods In this multicentre, randomised, open-label, phase 3 trial done at 29 hospitals in China, eligible patients were aged 18-70 years, had histopathogically confirmed stage II-IIIA NSCLC, had complete resection up to 8 weeks before random assignment, were treatment-naive, and had confirmed activation mutation in exon 19 or exon 21 of the EGFR gene. Participants were randomly assigned (1:1) with an interactive web-based response system to receive either oral icotinib 125 mg thrice daily for 2 years or four 21-day cycles of intravenous chemotherapy (vinorelbine 25 mg/m(2) on days 1 and 8 of each cycle plus cisplatin 75 mg/m(2) on day 1 of each cycle for adenocarcinoma or squamous carcinoma; or pemetrexed 500 mg/m(2) plus cisplatin 75 mg/m(2) on day 1 every 3 weeks for non-squamous carcinoma). The primary endpoint was disease-free survival assessed in the full analysis set. Secondary endpoints were overall survival assessed in the full analysis set and safety assessed in all participants who received study drug. This trial is registered with ClinicalTrials.gov, NCT02448797. Findings Between June 8, 2015, and August 2, 2019, 322 patients were randomly assigned to icotinib (n=161) or chemotherapy (n=161); the full analysis set included 151 patients in the icotinib group and 132 in the chemotherapy group. Median follow-up in the full analysis set was 24.9 months (IQR 16.6-36.4). 40 (26%) of 151 patients in the icotinib group and 58 (44%) of 132 patients in the chemotherapy group had disease relapse or death. Median disease-free survival was 47.0 months (95% CI 36.4-not reached) in the icotinib group and 22.1 months (16.8-30.4) in the chemotherapy group (stratified hazard ratio [HR] 0.36 [95% CI 0.24-0.55]; p<0.0001). 3-year disease-free survival was 63.9% (95% CI 51.8-73.7) in the icotinib group and 32.5% (21.3-44.2) in the chemotherapy group. Overall survival data are immature with 14 (9%) deaths in the icotinib group and 14 (11%) deaths in the chemotherapy. The HR for overall survival was 0.91 (95% CI 0.42-1.94) in the full analysis set. Treatment-related serious adverse events occurred in two (1%) of 156 patients in the icotinib group and 19 (14%) of 139 patients in the chemotherapy group. No interstitial pneumonia or treatment-related death was observed in either group. Interpretation Our results suggest that compared with chemotherapy, icotinib significantly improves disease-free survival and has a better tolerability profile in patients with EGFR-mutant stage II-IIIA NSCLC after complete tumour resection. Copyright (C) 2021 Elsevier Ltd. All rights reserved.

Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations

Epidermal Growth Factor Receptor‐tyrosine Kinase Inhibitor Therapy is Effective As First‐line Treatment of Advanced Non‐small‐cell Lung Cancer with Mutated EGFR: A Meta‐analysis from Six Phase III Randomized Controlled Trials

Gefitinib or Erlotinib Vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

Final Overall Survival and Updated Biomarker Analysis Results from the Randomized Phase Iii Icogen Trial

Icotinib Versus Chemotherapy As Adjuvant Treatment for Stage II–IIIA EGFR-mutant Non-Small-cell Lung Cancer (EVIDENCE): a Randomised, Open-Label, Phase 3 Trial

Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer.

A Bayesian Network Comparison of Different Agents or Regimens As First-Line Treatment for Advanced EGFR-mutated NSCLC.

Clinical efficacy and safety of adjuvant EGFR‐TKIs for resected stage IB lung adenocarcinoma: A real‐world study based on propensity score matching

Comparison of Adjuvant Target Therapy, Immunotherapy, and Chemotherapy for Resected EGFR-Mutant NSCLC – an Updated Network Meta-Analysis of 3300 Patients

The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer

The role of EGFR-TKIs as adjuvant therapy in EGFR mutation-positive early-stage NSCLC: A meta-analysis

CTONG1104: Adjuvant Gefitinib Versus Chemotherapy for Resected N1-N2 NSCLC with EGFR Mutation-Final Overall Survival Analysis of the Randomized Phase III Trial 1 Analysis of the Randomized Phase III Trial.

Randomized controlled trial of chemotherapy plus geiftinib as ifrst-line treatment for patients with advancedEGFR mutation-positive lung adenocarcinoma

REPORT- Clinical outcomes of using second - versus first-Generation EGFR-tkis for the First-Line treatment of advanced NSCLC patients with EGFR mutations: A meta-analysis

Adjuvant EGFR-TKI therapy in resected EGFR-mutation positive non-small cell lung cancer: A real-world study

P1.15-19 Treatment of Choice for First-Line Therapy of EGFR-Mutated Stage IIIB Lung Adenocarcinoma Based on the Real World Data

Comparison of the efficacy and safety of first-line treatments based on clinicopathological characteristics for patients with advanced epidermal growth factor receptor mutated non-small-cell lung cancer: A systematic review and network meta-analysis

What We Have Learned From Adjuvant Therapy for Resected EGFR-Mutant Non–Small-Cell Lung Cancer

Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-cell Lung Cancer Harboring EGFR Mutations.

Optimized selection of three major EGFR-TKIs in advanced EGFR-positive non-small cell lung cancer: A network meta-analysis

Therapeutic Efficacy Comparison of Six Major EGFR-TKIs in Non-Small-cell Lung Cancer Patients with an Activating EGFR Mutation: A Network Meta-Analysis.